Literature DB >> 7421873

Disorders of lipid metabolism in muscle.

S Di Mauro, C Trevisan, A Hays.   

Abstract

At rest and during sustained exercise, lipids are the main source of energy for muscle. Free fatty acids become available to muscle from plasma free fatty acids and triglycerides, and from intracellular triglycride lipid droplets. Transport of long-chain fatty acyl groups into the mitochondria requires esterification and de-esterification with carnitine by the "twin" enzymes carnitine palmityltransferase (CPT) I and II, bound to the outer and inner faces of the inner mitochondrial membrane. Carnitine deficiency occurs in two clinical syndromes. (1) In the myopathic form, there is weakness; muscle biopsy shows excessive accumulation of lipid droplets; and the carnitine concentration is markedly decreased in muscle but normal in plasma. (2) In the systemic form, there are weakness and recurrent episodes of hepatic encephalopathy; muscle biopsy shows lipid storage; and the carnitine concentration is decreased in muscle, liver, and plasma. The etiology of carnitine deficiency is not known in either the myopathic or the systemic form, but administration of carnitine or corticosteroids has been beneficial in some patients. "Secondary" carnitine deficiency may occur in patients with malnutrition, liver disease, chronic hemodialysis, and, possibly, mitochondrial disorders. CPT deficiency causes recurrent myoglobinuria, usually precipitated by prolonged exercise or fasting. Muscle biopsy may be normal or show varying degrees of lipid storage. Genetic transmission is probably autosomal recessive, but the great male predominance (20/21) remains unexplained. In many cases, lipid storage myopathy is not accompanied by carnitine or CPT deficiency, and the biochemical error remains to be identified.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7421873     DOI: 10.1002/mus.880030502

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

Review 2.  Secondary mitochondrial pathology.

Authors:  R C Sengers; A M Stadhouders
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

3.  Progressive diaphyseal dysplasia and a low muscle carnitine.

Authors:  A M Bye; E Hodson; G Kewley; K Kozlowski
Journal:  Pediatr Radiol       Date:  1988

4.  Ultrastructural modifications of muscle in three types of compartment syndrome.

Authors:  P Hoffmeyer; J N Cox; D Fritschy
Journal:  Int Orthop       Date:  1987       Impact factor: 3.075

Review 5.  Organelle pathology in metabolic neuromuscular disease: an overview.

Authors:  L E Becker
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

6.  Effects of L-carnitine loading on the aerobic and anaerobic performance of endurance athletes.

Authors:  C Marconi; G Sassi; A Carpinelli; P Cerretelli
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1985

7.  Fatal lipid storage myopathy with deficiency of cytochrome-c-oxidase and carnitine. A contribution to the combined cytochemical-finestructural identification of cytochrome-c-oxidase in longterm frozen muscle.

Authors:  J Müller-Höcker; D Pongratz; T Deufel; J M Trijbels; W Endres; G Hübner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

8.  [Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function].

Authors:  M Leschke; K W Rumpf; T Eisenhauer; K Becker; U Bock; F Scheler
Journal:  Klin Wochenschr       Date:  1984-03-15

9.  Myoglobinuria in carnitine palmityltransferase deficiency.

Authors:  D Rowett
Journal:  Int Urol Nephrol       Date:  1982       Impact factor: 2.370

10.  Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial.

Authors:  Angelo Cecere; Francesco Ciaramella; Luciano Tancredi; Ciro Romano; Adriano Gattoni
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.